A recent study by Moutinho and colleagues [78] draws a great interest regarding AD treatment options by demonstrating that supplementing 5xFAD mice that carry inactivated HCAR2 with Niaspan—an FDA-approved formulation of niacin—significantly reduces plaque burden, neuronal dystrophy, and neuronal loss, while restoring working memory. This evidence concerns the gene HCAR2 and Alzheimer disease.